Table 2.
Summary of cost (US dollars) and outcome results in the base-case analysis
| Item | Nivolumab | Docetaxel | Difference |
|---|---|---|---|
| Mean LYs | |||
| PFS state | 0.37 | 0.07 | 0.30 |
| PS state | 0.82 | 0.82 | 0.00 |
| Total | 1.19 | 0.89 | 0.30 |
| Mean QALYs | |||
| PFS state | 0.29 | 0.05 | 0.24 |
| PS state | 0.26 | 0.26 | 0.00 |
| Total | 0.55 | 0.31 | 0.24 |
| Cost (US$) | |||
| PFS state | 22,707 | 410 | 22,297 |
| PS state | 16,622 | 16,646 | −24 |
| Dead state | 1270 | 1282 | −12 |
| Total | 40,599 | 18,338 | 22,261 |
| ICER ($) | |||
| Per LY | 74,126 | ||
| Per QALY | 93,307 | ||
ICER incremental cost-effectiveness ratio, LY life-year, PFS progression-free survival, PS progression survival, QALY quality-adjusted life-year